Ifosfamide-induced Catatonia - A Rare Presentation and Review of Ifosfamide-induced Central Nervous System Toxicity Along With Therapeutic Approaches.

IF 1.7 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-08-01 DOI:10.21873/anticanres.17694

Stanley Lyndon

引用次数: 0

Abstract

Background/aim: Ifosfamide is a well-known chemotherapeutic agent used to treat various cancer types but is associated with central nervous system toxicity, termed ifosfamide-induced encephalopathy (IIE). Rarely, this toxicity manifests as catatonia.

Case report: We present the case of a 61-year-old woman with diffuse large B-cell lymphoma who developed profound catatonia after ifosfamide infusion. Her symptoms resolved completely following a single intravenous dose of lorazepam.

Conclusion: This case underscores the importance of recognizing catatonia as a manifestation of IIE and supports the use of lorazepam as both a diagnostic and therapeutic intervention.

查看原文本刊更多论文

异环磷酰胺诱导的紧张症-异环磷酰胺诱导的中枢神经系统毒性及其治疗方法的罕见表现和综述。

背景/目的：异环磷酰胺是一种众所周知的化疗药物，用于治疗各种类型的癌症，但与中枢神经系统毒性有关，称为异环磷酰胺诱导脑病（IIE）。这种毒性很少表现为紧张症。病例报告：我们报告一例61岁女性弥漫性大b细胞淋巴瘤患者在异环磷酰胺输注后出现深度紧张症。单次静脉注射劳拉西泮后，她的症状完全消失。结论：本病例强调了将紧张症视为IIE表现的重要性，并支持使用劳拉西泮作为诊断和治疗干预措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.